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A B S T R A C T
Background: Low adherence to treatment of latent tuberculosis infection (TLTBI) diminishes TB
prevention efforts. This study examined the treatment completion rate among those who started TLTBI
and factors associated with adherence to TLTBI.
Methods: Patients who started TLTBI in New York City (NYC) Health Department chest clinics during
January 2002–August 2004were studied. TLTBI completion ratewere described and compared according
to patient demographic and clinical characteristics by regimen using univariate analysis and log-
binomial regression.
Results: A total of 15 035 patients started and 6788 (45.2%) completed TLTBI. Treatment completers
were more likely than non-completers to be 35 years old (52.5%, adjusted relative risk (aRR) = 1.2, 95%
conﬁdence interval (CI) = 1.1, 1.2), contacts to pulmonary TB patients (57.4%, aRR = 1.5, 95% CI = 1.4, 1.7),
treated by directly observed preventive therapy (DOPT) (71.4%, aRR = 1.3, 95% CI = 1.2, 1.3), and to have
received the rifamycin-based regimen (60.0%, aRR = 1.2, 95% CI = 1.1, 1.3). The completion rate with an
isoniazid regimen did not differ between HIV-infected and HIV-uninfected persons. Among those who
failed to complete, 3748 (47.8%) failed to return for isoniazid and 59 (14.7%) for rifamycin after the ﬁrst
month of medication dispensing.
Conclusions: Shorter regimen and DOPT increased completion rates for LTBI. Though efforts to improve
TLTBI completion need to address all groups, greater focus is needed for persons who are contacts and
HIV-infected, as they have higher risk of developing TB.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Treatment of latent tuberculosis infection (TLTBI) is a preven-
tionmeasure with the aim of reducing the risk of progression to TB
disease among the large pool of infected individuals. In the USA,
the recommended treatment for most persons with latent
tuberculosis infection (LTBI) is a 9-month regimen of isoniazid.1
A 4-month regimen of rifampin for adults and a 6-month regimen
for children is recommended for persons who cannot tolerate
isoniazid or who are contacts to patients with isoniazid-resistant
TB.1 The national objective for completing TLTBI is 85% for contacts
and 75% for others.2 However, since persons latently infected with
Mycobacterium tuberculosis are not symptomatic, adherence to 9
months of treatment is challenging. Health departments across the
USA report that completion rates of6months of isoniazid among
contacts range from 51% to 62%,3–5 well below the national* Corresponding author. Tel.: +1 212 442 2426; fax: +1 212 788 4127.
E-mail address: jli3@health.nyc.gov (J. Li).
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doi:10.1016/j.ijid.2009.05.007objectives. Persons infected with HIV exposed to an infectious TB
case were not more likely to complete TLTBI than HIV-uninfected
contacts (54% vs. 56%).4 Completion rates were higher in a public
health clinic (72%) when a shorter regimen (4 months of rifampin)
was offered.6–8 Much higher completion rates were seen (83%) in
an open label randomized trial comparing 4 months of rifampin
with 9 months of isoniazid with close follow-up.9
Poor adherence to treatment is not localized geographically. In
New York City (NYC), the completion rate among those who start
treatment for LTBI is far below the national objectives set forth by
the Centers for Disease Control and Prevention (CDC), even though
focused efforts have been made to improve TLTBI completion for
several years. If TLTBI cannot be successfully applied in a large
proportion of persons at risk for developing active disease, the
impact of TLTBI on reducing the burden of disease will be
compromised. In order to evaluate the effectiveness of existing
TLTBI activities and program indicators, TB control programs must
examine the outcome of TLTBI. Therefore, the objectives of this
study were to examine the completion rate among those who
started treatment of LTBI with regimens containing isoniazid orses. Published by Elsevier Ltd. All rights reserved.
J. Li et al. / International Journal of Infectious Diseases 14 (2010) e292–e297 e293rifamycin, and to identify factors associated with completing
TLTBI.
2. Methods
This was a retrospective cohort study, utilizing existing NYC
Health Department TB clinic and NYC TB registry data.
2.1. Study subjects
All patients who were prescribed either isoniazid or rifamycin
(rifampin or rifabutin) for treatment of LTBI in any of the ten NYC
Health Department chest clinics during January 2002–August 2004
were included. Patients screened and referred by non-Health
Department providers for evaluation of a positive tuberculin skin
test (TST), as well as those screened at NYC Health Department TB
clinics and who were eligible for and started TLTBI were included.
Persons were excluded from the analysis if they were (1) contacts
of patients with multidrug-resistant TB, or (2) not treated with an
isoniazid- or rifamycin-containing regimen. Treatment of contacts
thought to be infectedwith tubercle resistant to both isoniazid and
rifamycin is complicated because of various drug resistance
patterns of the index patients. Drug regimens are individualized
and usually do not include isoniazid and rifamycin.
2.2. Data collection and deﬁnitions
All data were abstracted from existing NYC Health Department
chest clinic databases and the NYC TB registry, collected routinely
for surveillance and case management purposes in NYC. The
information on demographic characteristics and clinical care
included age, sex, race and ethnicity, country of birth, length of
time in the USA, borough of residence, date of ﬁrst visit to a TB
clinic, date treatment for LTBI started, regimen, length (months) of
TLTBI, and risk for TB disease. The outcome variable of interest for
the study was completion of TLTBI.
The diagnosis of LTBI was based on information gathered from
TST results, chest radiographs, physical examination, and, in
certain circumstances, sputum examinations, following the CDC
and the American Thoracic Society (ATS) guidelines published in
2000.1 The presence of TB disease was ruled out before treatment
for LTBI was initiated.
Patientswho agreed to start LTBI treatmentwere dispensed a 1-
month supply of the prescribed drug on the same day. They were
scheduled for monthly follow-up appointments for medical
evaluation and dispensing of the next month’s supply of the drug.
They were instructed to call and come to clinic earlier than the
scheduled visit if they experienced adverse reactions. Patients who
did not keep their appointments were recalled at least twice. Those
who failed to return for follow-up were considered non-adherent.
The treatment regimen types were isoniazid alone and
rifamycin alone. Patients who started with isoniazid treatment
and subsequently switched to a rifamycin regimen for various
reasons were classiﬁed as receiving the rifamycin regimen. For
data analysis, patients aged 18 years were considered to have
completed treatment if they took 6–9 months of isoniazid daily or
twice weekly within a 9–12-month period, or 4 months of daily
rifamycin doses within 6 months. Patients younger than 18 years
of age were considered to have completed treatment if they took 9
or more months of daily or twice-weekly isoniazid within a 12-
month period, or 6 or more months of daily doses of rifamycin
within a 9-month period.
Risk classiﬁcation was assigned by the treating clinician and
recorded as one of the four following categories: (1) contact to a
patient with infectious TB disease; (2) persons with medical risk
factors such as having a TST conversion within two years of anegative TST, HIV infection, untreated or partially treated prior TB,
suspected TB with an abnormal chest radiograph, being younger
than ﬁve years of age with a positive TST, or having a clinical
condition associated with an increased risk of TB disease;1 (3)
persons with population risk factors such as: recent immigrants to
the USA (5 years) from countries with high TB prevalence,
homeless persons, residents and employees of congregate settings
such as prisons and jails, and healthcare facilities; and (4) persons
with low risk for developing TB disease – all others that do not fall
into one of the above categories.
2.3. Statistical analysis
All data analysiswas performed using SAS forWindows, version
8.02 (SAS Institute, Cary, NC, USA). TLTBI completion rate was
calculated as the percent of persons who completed TLTBI among
those who started. Completion rates were described by sub-
categories of demographic and clinical characteristics. Indepen-
dent variables that were signiﬁcantly associated with treatment
completion in bivariate analysis were further examined in
multivariate analysis using log-binomial regression.10,11 To
examine the reasons why non-completers did not return for
follow-up, we compared those who failed to return for treatment
after ﬁrst medical visit to those who failed to return for medication
after two or more medical visits according to demographic and
clinical factors using the Pearson Chi-square test or Fisher’s exact
test for categorical data.
3. Results
There were 15 035 patients who started TLTBI from January 1,
2002 to August 31, 2004 in a NYC Health Department chest clinic
and who met the study inclusion criteria. Excluded persons were
either contacts to a multidrug-resistant TB patient (n = 145) or
were not treated with an isoniazid- or rifamycin-containing
regimen (n = 12).
3.1. Treatment completion by type of regimen
Of 15 035 eligible study patients, 14 030 (93.3%) were treated
with isoniazid alone, and 1005 (6.7%) with rifamycin alone. The
overall TLTBI completion rate was 45.2% (6788/15 035). However,
the completion varied from 30% to 86% by regimen type,
demographic and clinical characteristics (Table 1). Patients on
rifamycin alone had a higher completion rate than those on
isoniazid alone (60% vs. 44%; p < 0.01). Among persons with
known HIV status, and receiving isoniazid alone, the treatment
completion rate did not differ between HIV-infected and HIV-
uninfected persons (55% vs. 56%, p = 0.88).
Of all patients who completed TLTBI, 89.3% of those on isoniazid
alone completedwithin 12months, and 98.9% of those on rifamycin
alone completed within 6 months. The median time to treatment
completion was 9 months (range 6–33 months) for isoniazid alone
and 4 months (range 4–21 months) for rifamycin alone.
Since the required duration of treatment differs for those
younger than 18 years of age, Figure 1 shows the percent of
treatment completion by type and duration of regimens for those
above and below this age cutoff. Within the same age group, 12–
16% higher completion was seen in those receiving shorter
regimens. Among those using the same medication in different
age groups, nearly 10% higher completion was also seen in shorter
duration regimens.
In bivariate analysis, patients whowere aged 35 year and older,
Asian, non-Hispanic black, Hispanic, non-US-born, contacts to TB
patients, and on directly observed preventive therapy (DOPT) at
any time during treatment, were more likely to complete
Table 1
Completion of TLTBI by characteristics of study subjects and drug regimen, NYC Health Department chest clinics, 1/2002–8/2004 (N = 15 035)
Number started TLTBI (% completed TLTBI)
INH alone RIF alone Total
Characteristic n (%) n (%) n (%)
Total 14 030 (44.1) 1005 (60.0) 15 035 (45.4)
Age, years
<18 3928 (40.3) 191 (52.4) 4119 (40.9)
18–24 2539 (39.9) 146 (61.6) 2685 (41.1)
25–34 3078 (41.6) 226 (59.3) 3304 (42.8)
35 4485 (51.5) 442 (63.1) 4927 (52.5)
Sex
Male 6879 (44.4) 436 (61.0) 7315 (45.4)
Female 7151 (43.8) 569 (59.2) 7720 (45.0)
Race/ethnicity
Asian 2245 (48.8) 162 (67.9) 2407 (50.1)
Non-Hispanic black 4810 (44.1) 302 (58.3) 5112 (44.9)
Non-Hispanic white 997 (38.6) 69 (65.2) 1066 (40.3)
Hispanic 4728 (44.2) 385 (58.7) 5113 (45.3)
Other/unknown 1250 (39.5) 87 (52.9) 1337 (40.4)
Country of birth
Non-US-born 11 821 (44.3) 862 (60.4) 12 683 (45.2)
US-born 2076 (44.5) 139 (56.8) 2215 (45.3)
Unknown 133 (27.8) 4 (75.0) 137 (29.2)
Risk group
Contact 2344 (55.7) 388 (67.8) 2732 (57.4)
Medical risk 1790 (51.4) 116 (67.2) 1906 (52.4)
Population risk 8984 (40.6) 451 (52.8) 9435 (41.1)
Low risk 912 (34.7) 50 (48.0) 962 (35.3)
Ever on DOPT
Yes 217 (70.5) 14 (85.7) 231 (71.4)
No 13 813 (43.7) 991 (59.6) 14 804 (44.7)
HIV serostatus
Positive 94 (55.3) 1 (0.0) 95 (54.7)
Negative 3057 (56.1) 328 (61.3) 3385 (56.6)
Unknown 10 879 (40.6) 676 (59.5) 11 555 (41.7)
TLTBI, treatment of latent tuberculosis infection; INH, isoniazid; RIF, rifampin; DOPT, directly observed preventive therapy.
J. Li et al. / International Journal of Infectious Diseases 14 (2010) e292–e297e294treatment (Table 2). In multivariate analysis, of all patients who
received isoniazid alone or rifamycin alone (Table 2), patients who
were 35 years and older, Asian, non-Hispanic black, Hispanic,
non-US-born, contacts, at increased medical or population risk for
TB, ever onDOPT or a regimen of rifamycin alonewere signiﬁcantly
more likely to complete TLTBI. The strongest factor was being a
contact to a TB patient (adjusted relative risk (aRR) = 1.5, 95%
conﬁdence interval (CI) = 1.4, 1.7). Being on a rifamycin regimenFigure 1. Treatment completion by regimen and duration of latent TB infection
treatment, NYC Health Department chest clinics, 1/2002–8/2004 (N = 15 035).was associated with a 20% greater likelihood of completing
treatment than being on an isoniazid regimen (aRR = 1.2, 95%
CI = 1.1, 1.3).
3.2. Reasons for non-completion of treatment
Of 8247 patients who failed to complete treatment, 40.5%
refused to continue, 38.9% were lost to follow-up, 3.8% moved out
of NYC, 2.4% stopped because of an adverse reaction to medication,
and 14.4% discontinued because of other reasons. Three patients
died prior to completion of TLTBI.
One hundred and ninety-two (1.3%) of 15 035 patients who
started TLTBI reported an adverse reaction to treatment, of whom
four (2.1%) completed treatment and 188 (97.9%) did not complete.
Of all patients who started TLTBI, patients receiving the rifamycin
regimen reported more adverse reactions to treatment than those
receiving the isoniazid regimen (4.3% vs. 1.1%, p < 0.001).
The potential factors associated with non-completion were
further examined among patients receiving an isoniazid or
rifamycin regimen, separately (Table 3). Among those who did
not complete the isoniazid regimen, 3748 (47.8%) failed to return
after the ﬁrst month of medication dispensing and 4097 (52.2%)
failed to return after 2 months of medication dispensing.
Patients who stopped coming to Health Department clinics for
isoniazid after the ﬁrstmonthweremore likely to be older than 18
years of age, female, and non-Hispanic black. The main reasons
given for stopping treatment were ‘refused to continue’ and ‘lost
to follow-up’.
Table 2
Crude and adjusted relative risk and 95% conﬁdence interval for TLTBI completion,
NYC Health Department chest clinics, 1/2002–8/2004 (N = 15 035)
Variable % TLTBI
completion
Crude RR
(95% CI)
Adjusted RR
(95% CI)a
Age, years
<18 40.9 0.95 (0.90, 1.01) 0.99 (0.93, 1.04)
18–24 41.1 0.96 (0.90, 1.02) 0.97 (0.92, 1.03)
25–34 42.8 Referent Referent
35 52.5 1.23 (1.17, 1.29) 1.16 (1.11, 1.22)
Race/ethnicity
Asian 50.1 1.24 (1.14, 1.35) 1.20 (1.10, 1.30)
Non-Hispanic black 44.9 1.11 (1.03, 1.21) 1.11 (1.02, 1.20)
Non-Hispanic white 40.3 Referent Referent
Hispanic 45.3 1.12 (1.04, 1.22) 1.10 (1.02, 1.19)
Other/unknown 40.4 1.00 (0.91, 1.10) 1.01 (0.92, 1.11)
Country of birth
Non-US-born 45.3 1.00 (0.95, 1.05) 1.08 (1.03, 1.13)
US-born 45.2 Referent Referent
Risk group
Contact 57.4 1.62 (1.48, 1.78) 1.51 (1.38, 1.66)
Medical risk 52.4 1.48 (1.35, 1.63) 1.45 (1.32, 1.60)
Population risk 41.1 1.16 (1.07, 1.27) 1.16 (1.07, 1.27)
Low risk 35.3 Referent Referent
Ever on DOPT
Yes 71.4 1.60 (1.47, 1.74) 1.26 (1.18, 1.34)
No 44.7 Referent Referent
TLTBI regimen
Isoniazid alone 44.1 Referent Referent
Rifamycin alone 60.0 1.36 (1.29, 1.44) 1.20 (1.14, 1.26)
TLTBI, treatment of latent tuberculosis infection; RR, relative risk; CI, conﬁdence
interval; DOPT, directly observed preventive therapy.
a Adjusted for variables listed in the table.
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14.7% failed to return after the ﬁrst month of medication
dispensing and 85.3% failed to return after 2 months of
medication dispensing. Patients who stopped coming to clinic
for rifamycin after the ﬁrst month were more likely to be 18 years
and older and contact to a TB patient, compared to those who
stopped after two or more visits. However, those who failed to
return after the ﬁrst month were not signiﬁcantly different from
those who failed to return after being on treatment for 2 months
according to gender, race and ethnicity, country of birth, HIV
status, and ever being on DOPT. Refusal to continue the treatment
was also the primary reason for stopping a rifamycin regimen after
the ﬁrst medical visit. But the proportion with an adverse reaction
in those who failed to complete a rifamycin regimen was 5.8 (9.9%
vs. 1.7% for those who failed to return after 1 month) to 6.8 (13.6%
vs. 2.0% for those who failed to return after 2 months) times
higher than for those who failed to complete an isoniazid regimen,
regardless of when the patient stopped treatment (Table 3).
Whenwe restricted the analysis to thosewho failed to complete
and were under 18 years of age, 92.2% of those who took rifamycin
and 66% of those who took isoniazid stopped treatment after 2
months. Similar ﬁndings were seen after excluding contacts. Of
thosewho stopped after2months of treatment, 82% had received
4-month daily rifamycin and 78% had received 6-month daily
isoniazid; however, as they were under 18 years of age, they were
considered to have not completed treatment. About 5% were
switched to non-Health Department medical providers after
treatment began.
4. Discussion
The overall completion rate of 45.2% seen in this study is similar
to ﬁndings of previous reports3–5 and higher than rates reported byothers,12,13 though not as high as some studies.7,8 This study
provides further evidence to support shorter treatment regimens
for increasing the completion rate. In the usual program setting, a
4–6-month rifamycin regimen was independently associated with
a 20% higher completion rate than the 9-month isoniazid regimen.
Similar ﬁndings of the effect of regimen duration on treatment
completion have been reported in other studies.6–8 In a rando-
mized trial, patients allocated to 4 months of daily rifampin were
20% more likely to complete treatment than those allocated to 9
months of daily isoniazid.6 In retrospective studies, patients
receiving 4 months of rifampin were 36% to 51% more likely to
complete treatment than patients receiving the longer isoniazid
regimen.7,8 However, inconsistent with some previous studies,7,8
more adverse reactions to rifamycin than to isoniazid were
observed in this study, which had a relatively large sample size.
Further evaluation of adverse reactions to rifamycin treatment is
needed. The interaction with other drugs, especially those used in
HIV treatment,14,15 and limited published data on its efﬁcacy
should be taken into account when treating LTBI with rifampin.
Nine months of daily isoniazid is still the primary choice for the
majority of persons with LTBI until more information on the
efﬁcacy and effectiveness of shorter regimens is available.
Although isoniazid therapy is 90% effective for thosewho complete
it, its effectiveness is limited by a low adherence rate. Like most of
the previous studies,3,4,7 adherence to LTBI treatment in this study
is associated with age, risk for TB disease, and DOPT. The higher
completion of treatment among contacts and those receiving DOPT
suggests that the program can do better when it comes to the high-
risk group with close monitoring. To increase the completion rate
among contacts and to bring the other sub-groups to the
completion level of contacts, TLTBI strategies may need to be
tailored to meet the needs of each subgroup, especially when the
targeted population is large and diverse.
In addition to poor adherence, long duration of treatment is
also costly given that more medication is prescribed and longer
case management is required. One of the less expensive andmore
effective ways to improved compliance is to shorten the length of
treatment of LTBI.16 Better adherence improves effectiveness of
the treatment.17–20 More short-course treatment options,21 like a
3-month regimen of once-weekly isoniazid plus rifapentine
(US PHS TBTC Study 26, http://clinicaltrials.gov/ct2/show/
NCT00023452?term=tuberculosis%2C+rifapentine&rank=5), or a
4-month regimen of rifampin (http://www.muhc.ca/media/
news/item/?item id=105612) are currently under evaluation
and may become additional treatment options for LTBI in the
future.
This study also revealed that a crucial time to prevent patients
from stopping treatment may be the initial medical evaluation,
with close follow-up in the ﬁrst month, especially among those
receiving treatment with isoniazid, since a large percentage of
patients were lost to care immediately after the visit when
treatment was started. This ﬁnding is consistent with previous
studies showing that the adherence after the ﬁrstmonth of therapy
was a predictor of adherence to 6-months of TB therapy22 or to
TLTBI.9 Efforts to retain patients in TLTBI should begin at the ﬁrst
clinic visit when the regimen is prescribed. TLTBI requires
considerable commitment on the part of those receiving treat-
ment.9,13 Physicians should recognize patient decision-making
abilities, understand patient concerns, and participate in the
patient decisions about their medications.23 Communication
between healthcare providers and patients at the initial clinical
evaluation on the importance of taking TLTBI and the necessity of
prolonged treatment may have a positive impact on patient
compliance. Healthcare providers who believe in TLTBI can
motivate patients who are simply infected with M. tuberculosis
and not symptomatic.17,24,25
Table 3
Comparison of demographic and clinical characteristics by time discontinuing treatment among non-completers, NYC Health Department chest clinics, 1/2002–8/2004
(N = 8247)
Isoniazid alone Rifamycin alone
Failed to return after
1st month of
medication
dispensing
Failed to return after
2 months
p-Value Failed to return
after 1st month
of medication
dispensing
Failed to return
after 2 months
p-Value
Characteristic n (%) n (%) n (%) n (%)
Total 3748 4097 59 343
Age, years
<18 796 (21.2) 1549 (37.8) <0.001 6 (10.2) 85 (24.8) 0.013
18–24 788 (21.0) 738 (18.0) <0.001 9 (15.3) 47 (13.7) 0.751
25–34 1035 (27.6) 763 (18.6) <0.001 16 (27.1) 76 (22.2) 0.402
35 1129 (30.1) 1047 (25.6) <0.001 28 (47.5) 135 (39.4) 0.242
Sex
Male 1712 (45.7) 2115 (51.6) <0.001 30 (50.8) 140 (40.8) 0.150
Female 2036 (54.3) 1982 (48.4) 29 (49.2) 203 (59.2)
Race/ethnicity
Asian 531 (14.2) 619 (15.1) 0.239 8 (13.6) 44 (12.8) 0.877
Non-Hispanic black 1343 (35.8) 1346 (32.9) 0.005 13 (22.0) 113 (32.9) 0.095
Non-Hispanic white 315 (8.4) 297 (7.2) 0.057 6 (10.2) 18 (5.2) 0.141
Hispanic 1174 (31.3) 1464 (35.7) <0.001 26 (44.1) 133 (38.8) 0.442
Other/unknown 385 (10.3) 371 (9.1) 0.068 6 (10.2) 35 (10.2) 0.994
Country of birth
Non-US-born 3150 (84.0) 3446 (84.1) 0.937 52 (88.1) 289 (84.3) 0.443
US-born 540 (14.4) 613 (15.0) 0.488 7 (11.9) 53 (15.5) 0.475
Unknown 58 (1.5) 38 (0.9) 0.013 0 (0.0) 1 (0.3) 1.000
Risk group
Contact 448 (12.0) 591 (14.4) <0.001 38 (64.4) 87 (25.4) <0.001
Medical risk 400 (10.7) 470 (11.5) 0.260 4 (6.8) 34 (9.9) 0.447
Population risk 2592 (69.2) 2748 (67.1) 0.048 12 (20.3) 201 (58.6) <0.001
Low risk 308 (8.2) 288 (7.0) 0.047 5 (8.5) 21 (6.1) 0.497
Ever on DOPT
Yes 19 (0.5) 45 (1.1) 0.004 1 (1.7) 1 (0.3) 0.157
No 3729 (99.5) 4052 (98.9) 58 (98.3) 342 (99.7)
HIV serostatus
Positive 16 (0.4) 26 (0.6) 0.208 1 (1.7) 0 (0.0) 0.148
Negative 568 (15.2) 774 (18.9) <0.001 17 (28.8) 110 (32.1) 0.619
Unknown 3164 (84.4) 3297 (80.5) <0.001 41 (69.5) 233 (67.9) 0.812
Reason for non-completion
Refused to continue 1677 (44.7) 1378 (33.6) <0.001 26 (44.1) 93 (27.1) 0.008
Lost to follow-up 1551 (41.4) 1406 (34.3) <0.001 19 (32.2) 77 (22.4) 0.105
Adverse reaction 76 (2.0) 70 (1.7) 0.296 8 (13.6) 34 (9.9) 0.398
MD’s decision 103 (2.7) 92 (2.2) 0.153 1 (1.7) 15 (4.4) 0.331
Moved 131 (3.5) 164 (4.0) 0.238 1 (1.7) 5 (1.5) 0.890
Other 210 (5.6) 987 (24.1) <0.001 4 (6.8) 119 (34.7) <0.001
DOPT, directly observed preventive therapy.
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whenever possible, especially for children, contacts, and HIV-
infected persons, as the usefulness of DOPT in improving
adherence is recognized in this study as well as in other
studies.26,27 DOPT is often available via the public health programs
and can be performed at many locations such as clinics, schools,
homes, work sites, and day care programs. Patients should be
providedwritten information about potential adverse effects of the
medications at the start of treatment. Providing tools to improve
adherence such as taking pills at the same time of each day, and
incentives such as transportation cost, and small gifts can be
effective.6,28,29 Follow-up by phone call within 1–2 weeks after
starting treatment to check for adverse effects and reminding
patients to continue the medicine, reminder calls before appoint-
ments, and prompt follow-up for missed appointments will likely
improve adherence.30 Wait time at clinics should be minimized.
During each monthly visit, importance of adherence should be
emphasized. While no single intervention can be said to be mosteffective, the combination of several of the above is highly
recommended.
This study has several limitations. First, the use of existing
registry data restricted our ability to answer some important
questions related to poor adherence such as: why most non-
completers quit after treatment initiation, howmany of those who
do not return to care are due to adverse reactions to medications,
and, what is the physician’s role in patient compliance with
treatment? Second, some subgroups, homeless and drug abusers,
were not examined in this analysis because this information was
not available for over 93% of study patients. Third, others have
reported that patient beliefs in the beneﬁt of taking preventive
therapy and the perception of low risk of progressing to active TB
without LTBI treatment13 signiﬁcantly affect treatment comple-
tion. However, this information was not available for examination
in this study. Fourth, the completion rate may have been
underestimated, especially for persons under 18 years of age, as
many of the children with LTBI were referred to or transferred to
J. Li et al. / International Journal of Infectious Diseases 14 (2010) e292–e297 e297non-Health Departmentmedical providers for treatment, and their
treatment completion status was often not available to us. Lastly,
we measured compliance at the TB clinics only based on
medication dispensing on monthly visits. Lack of data on actual
amount of pills taken may lead to overestimation of compliance.
In summary, adherence to treatment of LTBI is not simply a
matter of patient compliance nor can it be easily addressed. It is a
complex problem that concerns the drug, treatment regimen and
duration, the patient’s needs and motivation to remain in
treatment, the physician’s role, strategies used by the program
to improve adherence, stafﬁng, and resources. This study could not
examine all the factors related to TLTBI completion and the overall
completion rate was low. However, completion rates varied in
different sub-groups suggesting that higher completion rates for
TLTBI can be achieved in a program setting. Current strategies need
to be evaluated and improved upon to develop more effective
interventions to enhance adherence and compliance. We can work
with TB control staff and physicians to enhance their roles in
helping patients to adhere. Efforts to improve TLTBI completion
should be tailored for different ages and risk groups. Evaluation of
shorter regimen needs to be done in clinical trials, which may
provide an additional important strategy to improve TLTBI
completion.
Conﬂict of interest
No conﬂict of interest to declare.
Disclaimer
The ﬁndings and conclusions in this report are those of the
authors and do not necessarily represent the views of the Centers
for Disease Control and Prevention.
Acknowledgments
The authors gratefully acknowledge Dr Cynthia R. Driver for her
important contribution to the study and her valuable review of this
manuscript. This work was supported by existing NYC Department
of Health and Mental Hygiene Bureau of TB Control funds.
This study was approved by the NYC Department of Health and
Mental Hygiene, Institutional Review Board, and was determined
by the Associate Director for Science of the National Center for HIV,
STD, and TB Prevention at the CDC not to be human subjects
research requiring IRB review.
References
1. Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing
and treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep
2000; 49 (RR-6): 1-51.
2. US Department of Health and Human Services. Healthy people 2010: under-
standing and improving health. 2nded.Washington,DC:GPO; 2000. Available at:
http://www.healthypeople.gov/document/html/objectives/14-13.htm (accessed
June 2009).
3. Reichler MR, Reves R, Bur S, Ford J, Thompson V, Mangura B, et al. Contact
Investigation Study Gr oup. Treatment of latent tuberculosis infection in con-
tacts of new tuberculosis cases in the United States. South Med J 2002;95:
414–20.4. Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH.
Outcomes of contact investigations of infectious tuberculosis patients. Am J
Respir Crit Care Med 2000;162:2033–8.
5. Leary L, Jereb J, Taylor Z. Aggregate reports for tuberculosis program evaluation
(ARPEs), United States 2000–2001, follow-up and treatment for contacts to
tuberculosis cases (Abstract). Presented at the National TB Controller Meeting,
June 2005. Atlanta, GA, USA.
6. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K.
Treatment completion and costs of a randomized trial of rifampin for 4 months
versus isoniazid for 9 months. Am J Respir Crit Care Med 2004;170:445–9.
7. Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, et al.
Improved adherence and less toxicity with rifampin vs. isoniazid for treatment
of latent tuberculosis: a retrospective study. Arch Intern Med 2006;166:1863–
70.
8. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement
of treatment completion for latent tuberculosis infection with 4 months of
rifampin. Chest 2006;130:1712–7.
9. Menzies D, Dion MJ, Francis D, Parisien I, Rocher I, Mannix S, et al. In closely
monitored patients, adherence in the ﬁrst month predicts completion of
therapy for latent tuberculosis infection. Int J Tuberc Lung Dis 2005;9:1343–8.
10. Greenland S. Model-based estimation of relative risks and other epidemiologic
measures in studies of common outcomes and in case-control studies. Am J
Epidemiol 2004;160:301–5.
11. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios
and differences. Am J Epidemiol 2005;162:199–205.
12. Lashley M. A targeted testing program for tuberculosis control and prevention
among Baltimore city’s homeless population. Public Health Nurs 2007;24:34–9.
13. Shieh FK, Snyder G, Horsburgh CR, Bernardo J, Murphy C, Saukkonen JJ. Pre-
dicting non-completion of treatment for latent tuberculous infection: a pro-
spective survey. Am J Respir Crit Care Med 2006;174:717–21.
14. Nijland HM, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RH,
et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis
and type 2 diabetes. Clin Infect Dis 2006;43:848–54.
15. Centers for Disease Control and Prevention (CDC). Notice to readers: updated
guidelines for the use of rifamycins for the treatment of tuberculosis among
HIV-infected patients taking protease inhibitors or nonnucleoside reverse
transcriptase inhibitors. MMWR Morb Mortal Wkly Rep 2004; 53: 37.
16. Reichman LB, Lardizabal A, Hayden CH. Considering the role of four months of
rifampin in the treatment of latent tuberculosis infection. Am J Respir Crit Care
Med 2004;170:832–5.
17. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general
review. Adv Tuberc Res 1970;17:28–106.
18. Comstock GW. How much isoniazid is needed for prevention of tuberculosis
among immunocompetent adults? Int J Tuberc Lung Dis 1999;3:847–50.
19. Polesky A, Farber HW, Gottlieb DJ, Park H, Levinson S, O’Connell JJ, et al.
Rifampin preventive therapy for tuberculosis in Boston’s homeless. Am J Respir
Crit Care Med 1996;154:1473–7.
20. Villarino ME, Ridzon R, Weismuller PC, Elcock M, Maxwell RM, Meador J, et al.
Rifampin preventive therapy for tuberculosis infection: experience with 157
adolescents. Am J Respir Crit Care Med 1997;155:1735–8.
21. Sterling TR. New approaches to the treatment of latent tuberculosis. Semin
Respir Crit Care Med 2008;29:532–41.
22. Sumartojo E. When tuberculosis treatment fails. A social behavioral account of
patient adherence. Am Rev Respir Dis 1993;147:1311–20.
23. Donovan JL, Blake DR. Patient non-compliance: deviance or reasoned decision-
making? Soc Sci Med 1992;34:507–13.
24. Grange JM, Festenstein F. The human dimension of tuberculosis control. Tuber
Lung Dis 1993;74:219–22.
25. Glassroth J. The physician’s role in tuberculosis prevention. Clin Chest Med
1989;10:365–74.
26. Davidson BL. A controlled comparison of directly observed therapy vs. self-
administered therapy for active tuberculosis in the urban United States. Chest
1998;114:1239–43.
27. Chaisson RE, Barnes GL, Hackman J, Watkinson L, Kimbrough L, Metha S, et al. A
randomized, controlled trial of interventions to improve adherence to isoniazid
therapy to prevent tuberculosis in injection drug users. Am J Med
2001;110:610–5.
28. Malotte CK, Hollingshead JR, LarroM. Incentives vs. outreach workers for latent
tuberculosis treatment in drug users. Am J Prev Med 2001;20:103–7.
29. Nyamathi AM, Christiani A, Nahid P, Gregerson P, Leake B. A randomized
controlled trial of two treatment programs for homeless adults with latent
tuberculosis infection. Int J Tuberc Lung Dis 2006;10:775–82.
30. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhan-
cing medication adherence. Cochrane Database Syst Rev 2008;2:CD000011.
